Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials

PURPOSE/BACKGROUND: Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS/PROCEDURES: Two phase 3 randomized, double-blind, placebo-controlled, parallel-group st...

Descripción completa

Detalles Bibliográficos
Autores principales: Adler, Lenard A., Adams, Julie, Madera-McDonough, Jessica, Kohegyi, Eva, Hobart, Mary, Chang, Denise, Angelicola, Mark, McQuade, Robert, Liebowitz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426730/
https://www.ncbi.nlm.nih.gov/pubmed/35652746
http://dx.doi.org/10.1097/JCP.0000000000001575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426730/
https://www.ncbi.nlm.nih.gov/pubmed/35652746
http://dx.doi.org/10.1097/JCP.0000000000001575

Ejemplares similares